Transfemoral implantation of Edwards SAPIEN-XT® transcatheter heart valve in a degenerated tricuspid bioprosthesis

Rogkakou, Christina; Braun, Peter; Kullmer, M.; Schöls, Wolfgang

doi:10.1016/j.jccase.2017.06.010

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent publications reported good results following implanted stent valves in the aortic or mitral position [ 11 , 12 ]. Since the first case of tricuspid valve-in-valve using an off-label Edwards SAPIEN valve (Edwards Lifesciences Corporation, Irvine, CA, USA) was reported, the literature on VIV implantation in failed tricuspid bioprostheses is reported in small case series and case reports [ 5 , 13 , 14 ]. Recently, registry data was reported by McElhinney, demonstrating that transcatheter tricuspid VIV implantation was hemodynamically and clinically beneficial in patients of various ages and underlying disease states.…”

Section: Discussionmentioning

confidence: 99%

Transcatheter Tricuspid Valve-in-Valve Replacement Using a J-Valve System for a Failed Tricuspid Bioprosthesis

Zhang

Xue

Miao

et al. 2022

Case Reports in Cardiology

View full text Add to dashboard Cite

Background. Redo operation for failed tricuspid bioprosthetic valves is associated with high morbidity and mortality. Transcatheter tricuspid valve-in-valve implantation has become an acceptable option for high-risk patients with a failed tricuspid bioprosthesis. We present a case of successful tricuspid valve-in-valve implantation using a J-valve in a failed tricuspid bioprosthesis position. Case Summary. A 48-year-old male, who had a failed tricuspid bioprosthesis, presented with right-side heart failure, right-to-left shunting at the atrial level, severe dyspnea, cyanosis, peripheral edema, hepatauxe, and ascites. After the interdisciplinary assessment, we successfully performed transcatheter tricuspid valve-in-valve implantation with the J-valve system. At 34-month postoperative follow-up, the patient had no symptoms of heart failure and the echocardiogram showed good valve position and well hemodynamic status. Conclusions. This case demonstrated that the J-valve system may be a new option for high-risk patients with a failed tricuspid bioprosthetic valve.

show abstract